HOTH News & Events

Hoth Therapeutics announced positive data from its HT-VA study, conducted under its Cooperative Research and Development Agreement, or CRADA, with the U.S. Department of Veterans Affairs and Emory University, demonstrating that parenteral GDNF, or Glial Cell-Derived Neurotrophic Factor, directly reprograms liver fat metabolism at the genetic level in a preclinical model of metabolic-associated fatty liver disease, or MAFLD. The data highlights statistically significant improvements in key genes responsible for fat production and fat metabolism, positioning GDNF as a potentially differentiated therapeutic approach targeting the root cause of fatty liver disease and metabolic dysfunction. Statistically significant reduction in Srebf1, a key gene driving fat production in the liver: Increased expression of Pparalpha, a central regulator of fat metabolism and fat burning; GDNF outperformed semaglutide in key gene expression markers tied to liver fat regulation; Demonstrated broad metabolic impact at the genetic level, not just weight reduction. Unlike existing therapies that primarily focus on weight loss, GDNF directly targets the biological mechanisms responsible for fat accumulation in the liver. Hoth plans to: Advance HT-VA findings into additional preclinical validation studies; Evaluate clinical development pathways for metabolic and liver diseases; and explore strategic partnerships and collaborations to accelerate development.

Hoth Therapeutics up 52% at $0.78 per share after HT-VA data

Hoth Therapeutics "announced positive data from its HT-VA study, conducted under its Cooperative Research and Development Agreement with the U.S. Department of Veterans Affairs and Emory University, demonstrating that parenteral GDNF (Glial Cell-Derived Neurotrophic Factor) directly reprograms liver fat metabolism at the genetic level in a preclinical model of metabolic-associated fatty liver disease."

Hoth Therapeutics announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 2.86M shares of its common stock at an offering price of 70c per share of common stock, in a registered direct offering. Additionally, in a concurrent private placement, the company issued and sold unregistered warrants to purchase up to an aggregate of 2.86M shares of common stock at an exercise price of 85c per share. The unregistered warrants will become exercisable six months following the date of issuance and will expire five and one-half years following the date of issuance. The closing of the offering is expected to occur on or about April 2, subject to the satisfaction of customary closing conditions. The aggregate gross proceeds to the company from the offering are expected to be approximately $2M, before deducting the placement agent's fees and other offering expenses payable by the company. The potential additional gross proceeds to the company from the unregistered warrants, if fully exercised on a cash basis, will be approximately $2.4M. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.